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Phenotypic characterisation by immunohistochemistry 
Figure 2. Isolated cells stained positive (green) for endothelial markers
and negative for muscular markers. Nuclei were stained by DAPI (blue).
AF488 Goat Anti-mouse fluorophore-conjugated antibody was used.
HPAE (human pulmonary arterial endothelial cells); SMC (smooth muscle
cells).
Phenotypic characterisation by flow cytometry  
Figure 3. Representative histograms show expression of surface markers 
associated with endothelial cells  and muscular cells on HPAE, SMC and 
CTEPH. EC-CTEPH were positive for all endothelial markers and negative 
for muscular markers. 
HP
AE
CT
EP
H-­
EC
SM
C
ULEX-­FITC
-­102101 103 104 105
0
19
38
56
75
CD105-­FITC
100 101 102 103 104
0
19
38
56
75
KDR-­APC
100 101 102 103 104
0
19
38
56
75
CD144-­PE
100 101 102 103 104
0
19
38
56
75
CD146-­FITC
100 101 102 103 104
0
19
38
56
75
CD34-­PECy7
100 101 102 103 104
0
19
38
56
75
UEA-­FITC
100 101 102 103 104
0
19
38
56
75
CD31-­FITC
100 101 102 103 104
0
19
38
56
75
CD146-­FITC
-­102101 103 104 105
0
19
38
56
75
CD34-­PeCy7
-­102 103 104 105
0
19
38
56
75
KDR-­APC
-­102 102 103 104 105
0
19
38
56
75
CD31-­FITC
-­102 102 103 104 105
0
19
38
56
75
CD105-­FITC
-­103 -­102 103 104 105
0
19
38
56
75
CD144-­PE
-­102101 103 104 105
0
19
38
56
75
CD146-­FITC
-­102 102 103 104 105
0
19
38
56
75
KDR-­APC
-­102 102 103 104 105
0
19
38
56
75
CD34-­PercP
-­102 102 103 104 105
0
19
38
56
75
CD144-­PE
-­102 102 103 104 105
0
19
38
56
75
CD31-­FITC
-­102 102 103 104 105
0
19
38
56
75
CD105-­FITC
-­102 102 103 104 105
0
19
38
56
75
ULEX-­FITC
-­102 102 103 104 105
0
19
38
56
75
SMA-­FITC
10
1
10
2
10
3
10
4
10
5
0
19
38
56
75
SMA-­FITC
10
0
10
1
10
2
10
3
10
4
0
19
38
56
75
SMA-­FITC
10
1
10
2
10
3
10
4
10
5
0
26
53
79
105
EC
-­C
TE
PH
Endothelial markers Muscular markers 
SM
C
HP
AE
Cell growth and migration  
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
1
2
3
Passage Number
F
o
ld
 e
xp
an
si
o
n
/d
ay
POPULATION DOUBLING TIMES
HPAE 
CTEPH-6
CTEPH-2
CTEPH-13
CTEPH-14
CTEPH-15
CTEPH-16
CTEPH-17
CTEPH-18
CTEPH-19
A
Ea
rly M
id
La
te
Su
pe
rla
te
0.0
0.2
0.4
0.6
0.8
MTT 
A
b
s
o
rv
a
n
c
e
 a
t 
5
7
0
n
m EC-CTEPH
HPAE
* ***
Ea
rly M
id
La
te
Su
pe
rla
te
0
20
40
60
80
100
KI67+ cells 
N
u
m
b
e
r 
o
f 
K
i6
7
+
 c
e
ll
s
/T
o
ta
l 
n
u
c
le
i
HPAE
EC-CTEPH
*
**
Figure 4. EC-CTEPH showed a hyperproliferative phenotype (A-B) with
significantly higher and durable viability assayed by MTT assay (C). HPAE
were used as controls. N=10, data are expressed as mean ± SD. * p<0.05
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Figure 5. Images of wound-healing of HPAE and EC-CTEPH after 24
hours. Representative graph showing quantification of the % of covered area
over time for both EC-CTEPH and HPAE. N=10, * p<0.05 .
Metabolism  
H P
A E
  
C T
E P
H
0
1
2
3
4
5
H IF -­1
R
N
A
  l
e
v
e
ls
/
-­a
c
ti
n
(r
e
la
ti
v
e
  e
x
p
re
s
s
io
n
)
ɑ
Figure 6. Diagram of metabolism related genes that can affect endothelial
cell metabolism towards glycolysis. HIF-1ɑ is higher expressed in CTEPH
patient cells assayed by RT-PCR. * p<0.05
*
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Conclusion
1. Isolated CTEPH cells are confirmed as being endothelial cells.
2. EC-CTEPH show a hyperproliferative phenotype.
3. Functionally, EC-CTEPH have a reduced capacity to migrate.
4. EC-CTEPH show alterations in metabolism towards anaerobic glycolysis.
Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a pulmonary vascular
disease caused by chronic obstruction of pulmonary arteries. Pulmonary endarterectomy
(PEA) is the golden standard therapy for CTEPH patients. During PEA surgery
obstructive thromboembolic material from the pulmonary arteries is removed, including
intima and superficial media. This material offers a unique opportunity to study CTEPH
at disease side. Endothelial cells line the entire vascular system and are essential for
maintaining the vascular homeostasis. Remodeling of pulmonary arteries through
proliferation of endothelial cells plays a major role in the pathogenesis of pulmonary
hypertension.
Aim
We aim to develop an in vitro model of CTEPH using
patient derived endothelial cell (EC-CTEPH) lines
after PEA and assay potential mitochondrial
disturbances and changes in metabolism to elucidate a
hyperproliferative phenotype that could explain
vascular changes occurring in CTEPH.
Methods
Freshly obstructive thromboembolic material obtained after PEA from CTEPH
patients is used for cell isolation. These PEA samples are minced into 1-2 mm
pieces and cultured in 0.2% gelatine coated 6-well plates in EGM-2 endothelial
medium (Lonza) at 37°C, 5% CO2 and 95% relative humidity. Colonies
appeared within 1-3 weeks of culture.
• Phenotypic characterisation: immunohistochemistry and flow
cytometry quantified expression of endothelial markers.
• Cell growth kinetics: cells were plated at a concentration of 3x104 in
24-well gelatine coated plates in 1mL of EGM-2 media. At each
subsequent passage, cells were counted and plated again at the same
cell concentration. Cell migration was measured by wound-healing
assay and expressed as the % of covered area.
• Metabolic changes were examined using RT-PCR.
Figure 1. Material obtained after PEA from CTEPH patients
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